-
31.发明公开公开(公告)号：US20230321196A1
公开(公告)日：2023-10-12
申请号：US18025266
申请日：2021-09-08
发明人： Kazuo Kitamura , Toshihiro Kita
CPC分类号： A61K38/22 , A61P31/16 , A61K9/0019
摘要： The present invention provides a means for preventing and/or treating a symptom of a viral infection in a subject affected by the viral infection without inducing any undesired serious side effect by optimizing the application method and the dose of a medicine containing AM or a derivative thereof as an active ingredient. One aspect of the present invention relates to a medicine for preventing or treating a symptom or disorder in a subject affected by a viral infection, the medicine containing adrenomedullin or a derivative thereof as an active ingredient.
-
公开(公告)号：US20230310471A1
公开(公告)日：2023-10-05
申请号：US17718673
申请日：2022-04-12
申请人： Alan Neil Glazier
发明人： Alan Neil Glazier
IPC分类号： A61K31/69 , A61K31/537 , A61K39/395 , A61K31/015 , A61K31/352 , A61K31/05 , A61K38/39 , A61K38/22 , A61K38/26 , A61K38/25 , A61K38/29 , A61K38/23 , A61K31/27 , A61K31/445 , A61K31/13 , A61K31/55 , A61K31/439 , A61K31/4178 , A61K31/40
CPC分类号： A61K31/69 , A61K31/537 , A61K39/3955 , A61K31/015 , A61K31/352 , A61K31/05 , A61K38/39 , A61K38/2235 , A61K38/26 , A61K38/25 , A61K38/2278 , A61K38/29 , A61K38/225 , A61K38/23 , A61K38/2228 , A61K38/22 , A61K31/27 , A61K31/445 , A61K31/13 , A61K31/55 , A61K31/439 , A61K31/4178 , A61K31/40
摘要： Disclosed herein are methods, devices, and systems for treating lens protein aggregation diseases by reducing the formation of proteins responsible for crowding, compacting, and/or causing increased internal lens pressure. Specifically disclosed herein are ophthalmologic compositions comprising one or more agents that regulate water, sodium, and/or calcium ion transport and/or storage through lens fiber cell channels, and/or reduce the formation and/or production of proteins responsible for crowding, compacting, and/or causing increased internal lens pressure.
-
公开(公告)号：US11744879B2
公开(公告)日：2023-09-05
申请号：US16642777
申请日：2018-08-31
申请人： FERRING B.V.
CPC分类号： A61K38/24 , A61K38/22 , A61P15/08 , G01N33/6893 , C07K16/26
摘要： Preparations including FSH, for example recombinant FSH, for use in the treatment of infertility in patients having high AMH and low bodyweight.
-
公开(公告)号：US11732019B2
公开(公告)日：2023-08-22
申请号：US17168325
申请日：2021-02-05
发明人： Mark Macielag , Raymond J. Patch , Rui Zhang , Martin A. Case , Mark J. Wall , Yue-Mei Zhang
IPC分类号： C07K14/575 , A61K47/68 , C07K16/24 , A61K9/00 , A61K38/17 , A61K38/26 , C07K1/06 , C07K1/107 , A61K47/64 , A61P3/10 , A61K49/00 , C07K1/12 , C07K1/18 , C07K5/02 , A61K47/60 , A61P3/08 , A61P3/00 , A61P3/04 , A61P3/06 , A61K38/22 , A61K45/06 , C07K16/00 , A61K38/00 , A61K39/00
CPC分类号： C07K14/575 , A61K9/0019 , A61K38/17 , A61K38/1709 , A61K38/22 , A61K38/26 , A61K45/06 , A61K47/60 , A61K47/64 , A61K47/68 , A61K47/6811 , A61K47/6845 , A61K47/6883 , A61K49/0032 , A61K49/0052 , A61K49/0056 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/08 , A61P3/10 , C07K1/061 , C07K1/1072 , C07K1/12 , C07K1/18 , C07K5/0205 , C07K14/57545 , C07K16/00 , C07K16/24 , A61K38/00 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/92 , C07K2317/94 , C07K2319/30
摘要： The present invention comprises compounds of Formula I.
wherein:
Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.-
公开(公告)号：US20230190945A1
公开(公告)日：2023-06-22
申请号：US18050659
申请日：2022-10-28
发明人： Tamer COSKUN , Hongchang QU
CPC分类号： A61K47/62 , A61K47/542 , A61K47/545 , A61K47/54 , A61P3/04 , A61P3/10 , A61K38/22
摘要： The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and/or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
-
公开(公告)号：US20230181693A1
公开(公告)日：2023-06-15
申请号：US17969971
申请日：2022-10-20
申请人： NEPSONE EHF
发明人： Birkir SVEINSSON
CPC分类号： A61K38/225 , A61K9/0014 , A61K38/23 , A61P17/02 , A61P17/06
摘要： A method for treating, remedying, or preventing inflammatory skin disorders by administering a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing an inflammatory skin disorder by administering topically and to the prepsoriatic rim a therapeutically effective dose of at least one an antagonist of a calcitonin gene-related peptide receptor in a pharmaceutically acceptable formulation.
-
公开(公告)号：US20230173031A1
公开(公告)日：2023-06-08
申请号：US18050890
申请日：2022-10-28
发明人： Luigina ROMANI , Enrico GARACI
IPC分类号： A61K38/22
CPC分类号： A61K38/2292
摘要： The present invention concerns Thymosin alpha 1 (Tα1) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.
-
公开(公告)号：US20230132279A1
公开(公告)日：2023-04-27
申请号：US18087273
申请日：2022-12-22
IPC分类号： A61K38/26 , A61K47/54 , A61K38/22 , A61K39/00 , A61K39/395
摘要： Provided herein, in some aspects, are delivery vehicles comprising a glycosphingolipid and an agent to be delivered attached to the glycosphingolipid. In some embodiments, the glycosphingolipid comprises an oligosaccharide and a short chain (e.g., C0-C3) ceramide. In some embodiments, the agent to be delivered is a therapeutic agent. The glycosphingolipid is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the glycosphingolipid described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the glycosphingolipid delivery vehicle are also provided.
-
公开(公告)号：US11622995B2
公开(公告)日：2023-04-11
申请号：US17226161
申请日：2021-04-09
IPC分类号： A61K38/17 , A61P3/10 , A61K38/22 , A61K38/26 , A61P3/08 , A61K9/00 , A61K45/06 , A61K9/08 , A61K9/10
摘要： Treatment of hyperinsulinemic hypoglycemia comprises administration of an effective amount of a glucagon-like peptide-1 receptor antagonist (GLP1RA) alone or in combination with an amylinomimetic agent or any anti-gastric emptying agent. Patients suffering from hyperinsulinemic hypoglycemia after bariatric surgery experience particular benefit, as there is no current method effective for their treatment. Prevention or reduction of acute adverse effects of postprandial hypoglycemia, such as palpitations, tremor, weakness, sweating, confusion, fatigue, blurred vision, seizures, or loss of consciousness, and prevention of chronic adverse effects of hyperinsulinemic hypoglycemia, such as cognitive impairment, can be achieved by treatment with GLP1RA.
-
40.发明申请公开(公告)号：US20230093887A1
公开(公告)日：2023-03-30
申请号：US17935667
申请日：2022-09-27
申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET LA RECHERCHE MEDICALE) , UNIVERSITE PAUL SABATIER TOULOUSE III , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
发明人： Philippe VALET , Cedric DRAY , Vincent MINVILLE , Bernard FRANCES , Francois LABASTE , Claire VINEL
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction. In particular, the present invention relates to a method of treating post-operative cognitive dysfunction in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an APJ receptor agonist.
-
-
-
-
-
-
-
-
-
搜索结果
4948 条记录 (耗时 0.046 秒)
